Associated tags: MDD, DSM-IV codes, TMS, Depression, Neuroscience, FDA, Mental health, Tic disorder, Transcranial magnetic stimulation, Quality of life, Patient, STIM, Pharmaceutical industry, Neuronetics
Locations: JAPAN, MT, CANADA, MICHIGAN, AETNA, THE RETREAT, MALVERN, PA, US, CENTRAL, UNITED STATES
Regenerative Medicine Advanced Therapy,
Major depressive disorder,
Marketing,
TMS,
Blue Cross Blue Shield Association,
Policy,
Quality of life,
Health policy,
Government,
STIM,
Neuronetics,
Medicare,
MDD,
Patient,
Practitioner,
Transcranial magnetic stimulation,
Pharmaceutical industry,
Nursing,
Health insurance,
UnitedHealth Group Effective immediately, Aetna now allows transcranial magnetic stimulation (TMS) treatment to be ordered and conducted under the supervision of behavioral health nurse practitioners for patients with major depressive disorder (MDD).
Key Points:
- Effective immediately, Aetna now allows transcranial magnetic stimulation (TMS) treatment to be ordered and conducted under the supervision of behavioral health nurse practitioners for patients with major depressive disorder (MDD).
- Also included in the update is the removal of a four-month psychotherapy trial before a patient becomes eligible to receive an initial course of treatment with TMS.
- This policy update builds on recent momentum from both commercial and government payers to expand coverage to TMS Therapy.
- Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payers to advocate for health policy changes.
Major depressive disorder,
Depression,
Marketing,
TMS,
Organization,
Ministry of Food and Drug Safety,
Quality of life,
MFDS,
OECD,
MDSAP,
Sale,
Ministry,
STIM,
MDD,
Patient,
D-8 Organization for Economic Cooperation,
Transcranial magnetic stimulation,
Health,
Neuronetics,
Pharmaceutical industry,
Food This marks the first international market where NeuroStar has obtained marketing authorization for the expanded indication and cutting-edge technologies.
Key Points:
- This marks the first international market where NeuroStar has obtained marketing authorization for the expanded indication and cutting-edge technologies.
- The NeuroStar 3.7 platform standardizes the NeuroStar hardware globally and includes advancements designed to streamline a clinician’s workflow, such as a touchscreen display with a biometric fingerprint reader.
- South Korea was also reported to have the greatest suicide rate among nations of the Organization of Economic Cooperation and Development (OECD)2.
- As a market leader in TMS within the South Korean market, NeuroStar aims to fill this unmet need and has partnered with distributor DK Healthcare to expand access to NeuroStar TMS.
Partnership,
Marketing,
Quality of life,
Drew,
STIM,
MDD,
Patient,
Gold,
Transcranial magnetic stimulation,
Neuronetics,
Bulldog,
Pharmaceutical industry “We are immensely honored to receive this recognition from the Bulldog PR Awards.
Key Points:
- “We are immensely honored to receive this recognition from the Bulldog PR Awards.
- Drew Robinson is an inspiring mental health advocate, and we share his passion for increasing awareness.
- Distinguished by their unique approach, they are the only PR awards program evaluated solely by journalists.
- NeuroStar TMS (transcranial magnetic stimulation) is a non-drug treatment that can help alleviate the burden of drug-resistant depression.
Depression,
Tic disorder,
OCD,
Marketing,
TMS,
Mental health,
Quality of life,
STIM,
Neuronetics,
Motor cortex,
DSM-IV codes,
MDD,
Patient,
FDA,
SVP,
Pharmaceutical industry,
Medical device “The unique design and functionality of the OCD MT Cap will enable clinicians to optimize treatment efficiency while upholding the highest standard of care for their patients.
Key Points:
- “The unique design and functionality of the OCD MT Cap will enable clinicians to optimize treatment efficiency while upholding the highest standard of care for their patients.
- NeuroStar stands out as the only TMS system with FDA clearance for MT Caps designed for both OCD and major depressive disorder (MDD).
- The OCD MT Cap shares the same advantages as the current MDD MT Cap.
- The OCD MT Cap will be available at select sites starting this month, with nationwide availability expected in Q4.
Depression,
Marketing,
TMS,
Blue Cross Blue Shield Association,
BCBS,
Policy,
Mental health,
Quality of life,
Health policy,
Government,
STIM,
Neuronetics,
MDD,
Patient,
Practitioner,
Transcranial magnetic stimulation,
Pharmaceutical industry,
Nursing This policy change increases patient access to the Company’s NeuroStar® Advanced Therapy for Mental Health by reducing the number of antidepressant medication attempts from four down to two prior to TMS treatment eligibility.
Key Points:
- This policy change increases patient access to the Company’s NeuroStar® Advanced Therapy for Mental Health by reducing the number of antidepressant medication attempts from four down to two prior to TMS treatment eligibility.
- The BCBS policy update builds on recent momentum from health payers to expand coverage to TMS Therapy.
- Neuronetics previously announced an updated TMS coverage policy through BlueCross BlueShield of Mississippi that allows non-physician practitioners, such as nurse practitioners, to prescribe TMS.
- Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payers to advocate for health policy changes.
MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023.
Key Points:
- MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023.
- The Company is scheduled to present at 1:00 pm Eastern Time the same day via webcast.
- A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.
- A replay of the webcast will be archived on the website for approximately 90 days.
Columbia University,
Depression,
Marketing,
TMS,
Quality of life,
STIM,
DSM-IV codes,
MDD,
Patient,
Physician,
Psychiatry,
Transcranial magnetic stimulation,
Health,
Mental health,
Pharmaceutical industry,
Radiology,
Neuronetics According to the survey, 77% of depression sufferers are either not actively treating their depression or have completely paused treatment at least once in their journey, highlighting a hidden epidemic.
Key Points:
- According to the survey, 77% of depression sufferers are either not actively treating their depression or have completely paused treatment at least once in their journey, highlighting a hidden epidemic.
- Survey results show that 75% of individuals with depression have undergone some period of treatment with medication and/or non-drug treatments.
- Depression medication users, past and present, appear to have the highest rate of dissatisfaction with their treatment compared to individuals who received other options.
- It is the most recent study of the experience of depression, its symptoms and severity, treatment, treatment-seeking behaviors, and barriers to treatment access from the perspective of depression sufferers.
Clifford Whittingham Beers,
Marketing,
TMS,
Workplace,
Mental health,
Quality of life,
Human,
Silver,
Certification,
STIM,
MDD,
Patient,
Transcranial magnetic stimulation,
MHA,
Nursing,
Neuronetics MALVERN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today that it has been awarded the Silver Bell Seal for Workplace Mental Health by Mental Health America (MHA).
Key Points:
- MALVERN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today that it has been awarded the Silver Bell Seal for Workplace Mental Health by Mental Health America (MHA).
- “We are incredibly grateful and humbled to be recognized by MHA,” said Keith J. Sullivan, President and CEO of Neuronetics.
- In 2019, MHA introduced the Bell Seal for Workplace Mental Health, the first-of-its-kind certification that recognizes employers who strive to improve employees’ well-being and create a psychologically safe workplace for all.
- "This recognition is a testament to our team's dedication in creating a supportive and nurturing workplace culture that prioritizes mental health," said Kara Thornton, Sr. Vice President of Human Resources at Neuronetics.
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023.
Key Points:
- MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023.
- The Company is scheduled to present at 12:30 pm Eastern Time the same day via webcast.
- A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.
- A replay of the webcast will be archived on the website for approximately 90 days.
Borrowing base,
Accountability Act,
Major depressive disorder,
Wi-Fi,
Network,
TMS,
Internet,
Blue Cross Blue Shield Association,
Telephone,
BCBS,
Policy,
SOFR,
Health policy,
Government,
Medicare,
Neuronetics,
UnitedHealth Group,
Health Insurance Portability and Accountability Act,
EBITDA,
MDD,
Patient,
Practitioner,
Webcast,
FDA,
Mental health,
Success,
Cryptocurrency,
Video game,
Mobile phone In the first quarter of 2023, U.S. treatment session revenue per active site was approximately $9,700 compared to approximately $9,874 in the first quarter of 2022.
Key Points:
- In the first quarter of 2023, U.S. treatment session revenue per active site was approximately $9,700 compared to approximately $9,874 in the first quarter of 2022.
- Gross margin for the first quarter of 2023 was 73.3%, a decrease of approximately 210 basis points from the first quarter of 2022 gross margin of 75.4%.
- Operating expenses during the first quarter of 2023 were $21.3 million, a marginal increase of $0.5 million, or 2%, compared to $20.8 million in the first quarter of 2022.
- EBITDA for the first quarter of 2023 was $(8.8) million as compared to the first quarter of 2022 EBITDA of $(9.5) million.
